Xylem Tops Q1 Profit Forecast as Sales Stall, Raises 2026 Revenue Outlook

Overview

• Xylem posted adjusted earnings of $1.12 per share, beating the $1.09 Wall Street estimate as investors nudged the stock up about 1.6% in premarket trading.
• Revenue came in at $2.1 billion versus a $2.11 billion forecast, with organic sales flat after stripping out currency effects and acquisitions.
• New orders reached $2.2 billion, up 3% on a reported basis but unchanged organically, which points to steady demand without underlying growth.
• Management raised full‑year revenue guidance to $9.2 billion to $9.3 billion and kept adjusted EPS guidance unchanged at $5.35 to $5.60.
• Adjusted EBITDA margin, a profit measure, improved 20 basis points to 20.6% as productivity savings and price increases offset softer volumes.